medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2022-16-23-148-155medsovet-7307Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYПерспективы использования препаратов группы агонистов рецепторов глюкагоноподобного пептида 1 в лечении неалкогольной жировой болезни печениProspects for the use of drugs from the group of agonists of glucagon-like peptide-1 receptors in the treatment of non-alcoholic fatty liver diseasehttps://orcid.org/0000-0001-9253-8075СуплотоваЛ. А.SuplotovaL. A.

Суплотова Людмила Александровна – доктор медицинских наук, профессор, заведующая курсом эндокринологии кафедры терапии.

625023, Тюмень, ул. Одесская, д. 54

Lyudmila A. Suplotova - Dr. Sci. (Med.), Professor, Head of the Endocrinology course of the Department of Therapy, Tyumen State Medical University.

54, Odesskaya St., Tyumen, 625023

suplotovala@mail.ruhttps://orcid.org/0000-0002-1723-540XФедороваА. И.FedorovaA. I.

Федорова Алена Игоревна - врач-эндокринолог.

625049, Тюмень, ул. Магнитогорская, д. 8

Alyona I. Fedorova - Еndocrinologist, Clinical Hospital “RZD-Medicine”.

8, Magnitogorskaya St., Tyumen, 625049

fai140996@mail.ruhttps://orcid.org/0000-0002-9973-9942КульмаметоваД. С.KulmametovaD. S.

Кульмаметова Диана Салимжановна - врач-эндокринолог.

626150, Тобольск, микрорайон 3б, д. 24

Diana S. Kulmametova - Еndocrinologist, Regional Hospital No. 3.

24, Мicrodistrict 3b, Tobolsk, 626150

d.kulmametova@mail.ruhttps://orcid.org/0000-0002-6329-593XДушинаТ. С.DushinaT. S.

Душина Татьяна Сергеевна - ассистент кафедры акушерства, гинекологии и реаниматологии с курсом клинической лабораторной диагностики.

625023, Тюмень, ул. Одесская, д. 54

Tatyana S. Dushina - Assistant of the Department of Obstetrics, Gynecology and Resuscitation with a сourse of Сlinical Laboratory Diagnostics Assistant of the Department of Obstetrics, Tyumen State Medical University.

54, Odesskaya St., Tyumen, 625023

dr.dushina@mail.ruhttps://orcid.org/0000-0003-4663-0289МакароваО. Б.MakarovaO. B.

Макарова Ольга Борисовна – кандидат медицинских наук, доцент, доцент курса эндокринологии кафедры терапии.

625023, Тюмень, ул. Одесская, д. 54

Olga B. Makarova - Cand. Sci. (Med.), Associate Professor, Аssociate Рrofessor of the course of Endocrinology of the Department of Therapy, Tyumen State Medical University.

54, Odesskaya St., Tyumen, 625023

dr.makarova@yahoo.comТюменский государственный медицинский университетРоссияTyumen State Medical UniversityRussian FederationКлиническая больница «РЖД-Медицина»РоссияClinical Hospital “RZD-Medicine”Russian FederationОбластная больница №3РоссияRegional Hospital No. 3Russian Federation202218012023023148155Copyright © Суплотова Л.А., Федорова А.И., Кульмаметова Д.С., Душина Т.С., Макарова О.Б., 20232023Суплотова Л.А., Федорова А.И., Кульмаметова Д.С., Душина Т.С., Макарова О.Б.Suplotova L.A., Fedorova A.I., Kulmametova D.S., Dushina T.S., Makarova O.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/7307

Неалкогольная жировая болезнь печени (НАЖБП) – одно из наиболее распространенных заболеваний печени. В значительной степени развитие данного заболевания ассоциировано с метаболическим синдромом. Имеется патогенетическая связь НАЖБП с ожирением, сахарным диабетом 2-го типа (СД2), сердечно-сосудистыми заболеваниями и хронической болезнью почек. Многочисленные исследования демонстрируют, что увеличение заболеваемости НАЖБП происходит параллельно с ростом распространенности ожирения и СД2. Ряд научных исследований в области медицины позволил идентифицировать основные патогенетические механизмы развития заболевания, а также возможности применения различных фармакологических препаратов для коррекции данных состояний. В настоящее время рассматривается возможность применения в перспективе группы лекарственных средств, которые имеют единый механизм контроля над процессом развития стеатоза печени и дальнейшего прогрессирования с формированием воспаления, цирроза и в некоторых случаях гепатоцеллюлярной карциномы. Особый интерес вызывает класс лекарственных препаратов, предназначенных для лечения СД2 и ожирения, – агонисты рецепторов глюкагоноподобного пептида 1 (арГПП-1). Был проведен поиск клинических исследований, метаанализов, литературных обзоров в базах данных и реестрах медицинских публикаций за 10-летний период. Изучены изменения антропометрических показаний, неинвазивных маркеров стеатоза печени, воспаления и фиброза, а также гистологические данные на фоне применения препаратов класса арГПП-1. Было продемонстрировано, что исследуемый класс препаратов может иметь значимый потенциал воздействия на НАЖБП. Однако необходимы дальнейшие исследования достаточной продолжительности с оценкой гистологической картины для анализа эффективности арГПП-1 в лечении НАЖБП.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases. To a large extent, the development of this disease is associated with metabolic syndrome. There is a pathogenetic association of NAFLD with obesity, type 2 diabetes mellitus (DM2), cardiovascular diseases and chronic kidney disease. Numerous studies demonstrate that an increase in the incidence of NAFLD occurs in parallel with an increase in the prevalence of obesity and DM 2. A number of scientific studies in the field of medicine have made it possible to identify the main pathogenetic mechanisms of the development of the disease, as well as the possibility of using various pharmacological drugs to correct these conditions. Currently, the possibility of using in the future a group of drugs that have a single mechanism for controlling the development of hepatic steatosis, and further progression with the formation of inflammation, cirrhosis and, in some cases, hepatocellular carcinoma, is being considered. Of particular interest is a class of drugs intended for the treatment of type 2 diabetes and obesity – glucagon-like peptide-1 receptor agonists (arGLP-1). A search was made of clinical studies, meta-analyses, literature reviews in databases and registries of medical publications over a period of 10 years. Changes in anthropometric indications, changes in non-invasive markers of liver steatosis, inflammation and fibrosis, as well as histological data on the background of the use of drugs of the arGLP-1 class were studied. It has been demonstrated that the study drug class may have a significant potential for impact on NAFLD. However, further studies with sufficient duration and histological evaluation are needed to fully evaluate the effectiveness of arGLP-1 in the treatment of NAFLD.

неалкогольная жировая болезнь печенистеатозметаболический синдромфармакотерапияагонисты рецепторов глюкагоноподобного пептида 1non-alcoholic fatty liver diseasesteatosismetabolic syndromepharmacotherapyglucagon-like peptide-1 receptor agonistsReferencesМаевская М.В., Котовская Ю.В., Ивашкин В.Т., Ткачева О.Н., Трошина Е.А., Шестакова М.В. и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;(2):216–253. https://doi.org/10.26442/00403660.2022.02.201363.Maevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V. et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii Arkhiv. 2022;(2):216–253. (In Russ.) https://doi.org/10.26442/00403660.2022.02.201363.Бабенко А.Ю., Лаевская М.Ю. Неалкогольная жировая болезнь печени – взаимосвязи с метаболическим синдромом. РМЖ. 2018;(1):34–40. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Nealkogolynaya_ghirovaya_bolezny_pecheni_vzaimosvyazi_s_metabolicheskim_sindromom.Babenko A.Yu., Laevskaya M.Yu. Non-alcoholic fatty liver disease–relationships with metabolic syndrome. RMJ. 2018;(1):34–40. (In Russ.) Available at: https://www.rmj.ru/articles/endokrinologiya/Nealkogolynaya_ghirovaya_bolezny_pecheni_vzaimosvyazi_s_metabolicheskim_sindromom.Pierantonelli I., Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1–e13. https://doi.org/10.1097/TP.0000000000002480.Pierantonelli I., Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. Transplantation. 2019;103(1):e1–e13. https://doi.org/10.1097/TP.0000000000002480.Day C.P., James O.F.W. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. https://doi.org/10.1016/s0016-5085(98)70599-2.Day C.P., James O.F.W. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. https://doi.org/10.1016/s0016-5085(98)70599-2.Caligiuri A., Gentilini A., Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575. https://doi.org/10.3390/ijms17091575.Caligiuri A., Gentilini A., Marra F. Molecular pathogenesis of NASH. Int J Mol Sci. 2016;17(9):1575. https://doi.org/10.3390/ijms17091575.Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M. et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6):993–999. https://doi.org/10.1016/j.jhep.2008.02.011.Ouyang X., Cirillo P., Sautin Y., McCall S., Bruchette J.L., Diehl A.M. et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6):993–999. https://doi.org/10.1016/j.jhep.2008.02.011.Tappy L., Lê K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90(1):23–46. https://doi.org/10.1152/physrev.00019.2009.Tappy L., Lê K.A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90(1):23–46. https://doi.org/10.1152/physrev.00019.2009.Jegatheesan P., De Bandt J.P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230. https://doi.org/10.3390/nu9030230.Jegatheesan P., De Bandt J.P. Fructose and NAFLD: the multifaceted aspects of fructose metabolism. Nutrients. 2017;9(3):230. https://doi.org/10.3390/nu9030230.Chandrasekaran K., Swaminathan K., Chatterjee S., Dey A. Apoptosis in HepG2 cells exposed to high glucose. Toxicol in Vitro. 2010;24(2):387–396. https://doi.org/10.1016/j.tiv.2009.10.020.Chandrasekaran K., Swaminathan K., Chatterjee S., Dey A. Apoptosis in HepG2 cells exposed to high glucose. Toxicol in Vitro. 2010;24(2):387–396. https://doi.org/10.1016/j.tiv.2009.10.020.Civera M., Urios A., Garcia-Torres M.L., Ortega J., Martinez-Valls J., Cassinello N. et al. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev. 2010;26(3):187–192. https://doi.org/10.1002/dmrr.1070.Civera M., Urios A., Garcia-Torres M.L., Ortega J., Martinez-Valls J., Cassinello N. et al. Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity. Diabetes Metab Res Rev. 2010;26(3):187–192. https://doi.org/10.1002/dmrr.1070.Кучерявый Ю.А., Маевская Е.А., Ахтаева М.Л., Краснякова Е.А. Неалкогольный стеатогепатит и кишечная микрофлора: есть ли потенциал пребиотических препаратов в лечении? Медицинский совет. 2013;(2):46–51. Режим доступа: https://www.med-sovet.pro/jour/article/view/963/0.Kucheryavy Y.A., Maevskaya E.A., Akhtaeva M.L., Krasnyakova E.A. Nonalcoholic steatohepatitis and intestinal microflora: the question of potential of prebiotic medicines. Meditsinskiy Sovet. 2013;(2):46–51. (In Russ.) Available at: https://www.med-sovet.pro/jour/article/view/963/0.Gambino R., Bugianesi E., Rosso C., Mezzabotta L., Pinach S., Alemanno N. et al. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. Int J Mol Sci. 2016;17(4):479. https://doi.org/10.3390/ijms17040479.Gambino R., Bugianesi E., Rosso C., Mezzabotta L., Pinach S., Alemanno N. et al. Different serum free fatty acid profiles in NAFLD subjects and healthy controls after oral fat load. Int J Mol Sci. 2016;17(4):479. https://doi.org/10.3390/ijms17040479.Салль Т.С., Щербакова Е.С., Ситкин С.И., Вахитов Т.Я., Бакулин И.Г., Демьянова Е.В. Молекулярные механизмы развития неалкогольной жировой болезни печени. Профилактическая медицина. 2021;(4):120–131. https://doi.org/10.17116/profmed202124041120.Sall T.S., Shcherbakova E.S., Sitkin S.I., Vakhitov T.Ya., Bakulin I.G., Demyanova E.V. Molecular mechanisms of non-alcoholic fatty liver disease development. Profilakticheskaya Meditsina. 2021;(4):120–131. (In Russ.) https://doi.org/10.17116/profmed202124041120.Bae C.S., Park S.H. The involvement of p38 MAPK and JNK activation in palmitic acid-induced apoptosis in rat hepatocytes. Journal of Life Science. 2009;19(8):1119–1124.Bae C.S., Park S.H. The involvement of p38 MAPK and JNK activation in palmitic acid-induced apoptosis in rat hepatocytes. Journal of Life Science. 2009;19(8):1119–1124.Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223. https://doi.org/10.1152/physrev.00063.2017.Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018;98(4):2133–2223. https://doi.org/10.1152/physrev.00063.2017.Пеньков Д.Н., Егоров А.Д., Мозговая М.Н., Ткачук В.А. Связь инсулиновой резистентности с адипогенезом: роль транскрипционных и секретируемых факторов. Биохимия. 2013;(1):14–26. Режим доступа: https://biochemistrymoscow.com/ru/archive/2013/78-01-0014.Penkov D.N., Egorov A.D., Mozgovaya M.N., Tkachuk V.A. Relationship between insulin resistance and adipogenesis: the role of transcription and secreted factors. Biochemistry (Moscow). 2013;(1):14–26. (In Russ.) Available at: https://biochemistrymoscow.com/ru/archive/2013/78-01-0014.Qiang G., Kong H.W., Xu S., Pham H.A., Parlee S.D., Burr A.A. et al. Lipodystrophy and severe metabolic dysfunction in mice with adipose tissue-specific insulin receptor ablation. Mol Мetab. 2016;5(7):480–490. https://doi.org/10.1016/j.molmet.2016.05.005.Qiang G., Kong H.W., Xu S., Pham H.A., Parlee S.D., Burr A.A. et al. Lipodystrophy and severe metabolic dysfunction in mice with adipose tissue-specific insulin receptor ablation. Mol Мetab. 2016;5(7):480–490. https://doi.org/10.1016/j.molmet.2016.05.005.Wu X., Chen K., Williams K.J. The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. Curr Opin Lipidol. 2012;23(4):334–344. https://doi.org/10.1097/MOL.0b013e3283544424.Wu X., Chen K., Williams K.J. The role of pathway-selective insulin resistance and responsiveness in diabetic dyslipoproteinemia. Curr Opin Lipidol. 2012;23(4):334–344. https://doi.org/10.1097/MOL.0b013e3283544424.Abulizi A., Perry R.J., Camporez J.P.G., Jurczak M.J., Petersen K.F., Aspichueta P. et al. A controlled‐release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J. 2017;31(7):2916–2924. https://doi.org/10.1096/fj.201700001R.Abulizi A., Perry R.J., Camporez J.P.G., Jurczak M.J., Petersen K.F., Aspichueta P. et al. A controlled‐release mitochondrial protonophore reverses hypertriglyceridemia, nonalcoholic steatohepatitis, and diabetes in lipodystrophic mice. FASEB J. 2017;31(7):2916–2924. https://doi.org/10.1096/fj.201700001R.Bechmann L.P., Hannivoort R.A., Gerken G., Hotamisligil G.S., Trauner M., Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–964. https://doi.org/10.1016/j.jhep.2011.08.025.Bechmann L.P., Hannivoort R.A., Gerken G., Hotamisligil G.S., Trauner M., Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56(4):952–964. https://doi.org/10.1016/j.jhep.2011.08.025.Mota M., Banini B.A., Cazanave S.C., Sanyal A.J. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1049–1061. https://doi.org/10.1016/j.metabol.2016.02.014.Mota M., Banini B.A., Cazanave S.C., Sanyal A.J. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. Metabolism. 2016;65(8):1049–1061. https://doi.org/10.1016/j.metabol.2016.02.014.Brandi G., Lorenzo S.D., Candela M., Pantaleo M.A., Bellentani S., Tovoli F. et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 2017;38(3):231–240. https://doi.org/10.1093/carcin/bgx007.Brandi G., Lorenzo S.D., Candela M., Pantaleo M.A., Bellentani S., Tovoli F. et al. Microbiota, NASH, HCC and the potential role of probiotics. Carcinogenesis. 2017;38(3):231–240. https://doi.org/10.1093/carcin/bgx007.Monsour Jr.H.P., Frenette C.T., Wyne K. Fatty liver: a link to cardiovascular disease–its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):21. https://doi.org/10.14797/mdcj-8-3-21.Monsour Jr.H.P., Frenette C.T., Wyne K. Fatty liver: a link to cardiovascular disease–its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):21. https://doi.org/10.14797/mdcj-8-3-21.Buechler C., Wanninger J., Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17(23):2801. https://doi.org/10.3748/wjg.v17.i23.2801.Buechler C., Wanninger J., Neumeier M. Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol. 2011;17(23):2801. https://doi.org/10.3748/wjg.v17.i23.2801.Engel J.A., Jerlhag E. Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy. CNS Drugs. 2014;28(10):875–886. https://doi.org/10.1007/s40263-014-0178-y.Engel J.A., Jerlhag E. Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy. CNS Drugs. 2014;28(10):875–886. https://doi.org/10.1007/s40263-014-0178-y.Кытикова О.Ю., Новгородцева Т.П., Денисенко Ю.К., Антонюк М.В., Гвозденко Т.А. Толл-подобные рецепторы в патофизиологии ожирения. Ожирение и метаболизм. 2020;(1):56–63. https://doi.org/10.14341/omet10336.Kytikova O.Y., Novgorodtseva T.P., Denisenko Yu.K., Antonyuk M.V., Gvozdenko T.A. Toll-like receptors in the pathophysiology of obesity. Obesity and Metabolism. 2020;(1):56–63. (In Russ.) https://doi.org/10.14341/omet10336.Dube P.E., Brubaker P.L. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res. 2004;36(11–12):755–760. https://doi.org/10.1055/s-2004-826159.Dube P.E., Brubaker P.L. Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res. 2004;36(11–12):755–760. https://doi.org/10.1055/s-2004-826159.Галстян Г.Р., Каратаева Е.А., Юдович Е.А. Эволюция агонистов рецепторов глюкагоноподобного пептида-1 в терапии сахарного диабета 2-го типа. Сахарный диабет. 2017;(4):286–298. https://doi.org/10.14341/DM8804.Galstyan G.R., Karataeva E.A., Yudovich E.A. Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes. Diabetes Mellitus. 2017;(4):286–298. (In Russ.) https://doi.org/10.14341/DM8804.Раскина К. Долгоживущий человеческий аналог ГПП-1. Актуальная эндокринология. 2015;6(1). Режим доступа: https://actendocrinology.ru/archives/2507.Raskina K. Long-lived human analogue of GLP-1. Aktualnaya Endokrinologiya. 2015;6(1). (In Russ.) Available at: https://actendocrinology.ru/archives/2507.Халимов Ю.Ш., Кузьмич В.Г. Органопротективные эффекты агонистов рецепторов глюкагоноподобного пептида 1-го типа по результатам доказательных исследований сердечно-сосудистой безопасности. Медицинский совет. 2019;(21):189–197. https://doi.org/10.21518/2079-701X-2019-21-189-197.Khalimov Y.S., Kuzmich V.G. Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies. Meditsinskiy Sovet. 2019;(21):189–197. (In Russ.) https://doi.org/10.21518/2079-701X-2019-21-189-197.Scrocchi L.A., Brown T.J., Maclusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Мed. 1996;2(11):1254–1258. https://doi.org/10.1038/nm1196-1254.Scrocchi L.A., Brown T.J., Maclusky N., Brubaker P.L., Auerbach A.B., Joyner A.L., Drucker D.J. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Мed. 1996;2(11):1254–1258. https://doi.org/10.1038/nm1196-1254.Buteau J. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Мetab. 2008;34(Suppl. 2):S73–77. https://doi.org/10.1016/S1262-3636(08)73398-6.Buteau J. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Мetab. 2008;34(Suppl. 2):S73–77. https://doi.org/10.1016/S1262-3636(08)73398-6.Fehmann H.C., Habener J.F. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130(1):159–166. https://doi.org/10.1210/endo.130.1.1309325.Fehmann H.C., Habener J.F. Insulinotropic hormone glucagon-like peptide-I (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Endocrinology. 1992;130(1):159–166. https://doi.org/10.1210/endo.130.1.1309325.Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. https://doi.org/10.1016/j.cmet.2013.04.008.Campbell J.E., Drucker D.J. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. https://doi.org/10.1016/j.cmet.2013.04.008.Cryer P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–1048. https://doi.org/10.1210/en.2011-1499.Cryer P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012;153(3):1039–1048. https://doi.org/10.1210/en.2011-1499.Buse J.B., Sesti G., Schmidt W.E., Montanya E., Chang C.T., Xu Y. et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–1303. https://doi.org/10.2337/dc09-2260.Buse J.B., Sesti G., Schmidt W.E., Montanya E., Chang C.T., Xu Y. et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010;33(6):1300–1303. https://doi.org/10.2337/dc09-2260.Henry R.R., Buse J.B., Sesti G., Davies M.J., Jensen K.H., Brett J. et al. Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocr Pract. 2011;17(6):906–913. https://doi.org/10.4158/ep.17.6.906.Henry R.R., Buse J.B., Sesti G., Davies M.J., Jensen K.H., Brett J. et al. Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program. Endocr Pract. 2011;17(6):906–913. https://doi.org/10.4158/ep.17.6.906.Monami M., Dicembrini I., Nreu B., Andreozzi F., Sesti G., Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017;54(12):1101–1114. https://doi.org/10.1007/s00592-017-1054-2.Monami M., Dicembrini I., Nreu B., Andreozzi F., Sesti G., Mannucci E. Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials. Acta Diabetol. 2017;54(12):1101–1114. https://doi.org/10.1007/s00592-017-1054-2.Fan H., Pan Q.R., Xu Y., Yang X.C. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras de Endocrinol Metabol. 2013;57(9):702–708. https://doi.org/10.1590/s0004-27302013000900005.Fan H., Pan Q.R., Xu Y., Yang X.C. Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arq Bras de Endocrinol Metabol. 2013;57(9):702–708. https://doi.org/10.1590/s0004-27302013000900005.Cusi K., Sattar N., García-Pérez L.-E., Pavo I., Yu M., Robertson K.E. et al. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diab Med. 2018;35(10):1434–1439. https://doi.org/10.1111/dme.13697.Cusi K., Sattar N., García-Pérez L.-E., Pavo I., Yu M., Robertson K.E. et al. Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme. Diab Med. 2018;35(10):1434–1439. https://doi.org/10.1111/dme.13697.Aroda V.R., Rosenstock J., Terauchi Y., Altuntas Y., Lalic N.M., Morales Villegas E.C. et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732. https://doi.org/10.2337/dc19-0749.Aroda V.R., Rosenstock J., Terauchi Y., Altuntas Y., Lalic N.M., Morales Villegas E.C. et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care. 2019;42(9):1724–1732. https://doi.org/10.2337/dc19-0749.Гоникова З.З., Никольская А.О., Кирсанова Л.А., Шагидулин М.Ю., Онищенко Н.А., Севастьянов В.И. Сравнительный анализ эффективности стимуляции процессов регенерации печени клетками костного мозга и общей РНК этих клеток. Вестник трансплантологии и искусственных органов. 2019;(1):113–121. https://doi.org/10.15825/1995-1191-2019-1-113-121.Gonikova Z.Z., Nikolskaya A.O., Kirsanova L.A., Shagidulin M.Yu., Onishchenko N.A., Sevastyanov V.I. The comparative analysis of the effectiveness of stimulation of liver regeneration by bone marrow cells and total RNA of these cells. Vestnik Transplantologii i Iskusstvennykh Organov. 2019;(1):113–121. (In Russ.) https://doi.org/10.15825/1995-1191-2019-1-113-121.Feng W., Bi Y., Li P., Yin T.T., Gao C.X., Shen S.M. et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease. J Diabetes. 2017;9(8):800–809. https://doi.org/10.1111/jdi.12888.Feng W., Bi Y., Li P., Yin T.T., Gao C.X., Shen S.M. et al. Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non‐alcoholic fatty liver disease. J Diabetes. 2017;9(8):800–809. https://doi.org/10.1111/jdi.12888.Gluud L.L., Knop F.K., Vilsbоll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4(12):e005325. https://doi.org/10.1136/bmjopen-2014-005325.Gluud L.L., Knop F.K., Vilsbоll T. Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. BMJ Open. 2014;4(12):e005325. https://doi.org/10.1136/bmjopen-2014-005325.Sjоberg K.A., Holst J.J., Rattigan S., Richter E.A., Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab. 2014;306(4):E355–E362. https://doi.org/10.1152/ajpendo.00283.2013.Sjоberg K.A., Holst J.J., Rattigan S., Richter E.A., Kiens B. GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am J Physiol Endocrinol Metab. 2014;306(4):E355–E362. https://doi.org/10.1152/ajpendo.00283.2013.Nogueiras R., Pérez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G. et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009;29(18):5916–5925. https://doi.org/10.1523/JNEUROSCI.5977-08.2009.Nogueiras R., Pérez-Tilve D., Veyrat-Durebex C., Morgan D.A., Varela L., Haynes W.G. et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci. 2009;29(18):5916–5925. https://doi.org/10.1523/JNEUROSCI.5977-08.2009.Richards P., Parker H.E., Adriaenssens A.E., Hodgson J.M., Cork S.C., Trapp S. et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014;63(4):1224–1233. https://doi.org/10.2337/db13-1440.Richards P., Parker H.E., Adriaenssens A.E., Hodgson J.M., Cork S.C., Trapp S. et al. Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes. 2014;63(4):1224–1233. https://doi.org/10.2337/db13-1440.Baggio L.L., Ussher J.R., McLean B.A., Cao X., Kabir M.G., Mulvihill E.E. et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6(11):1339–1349. https://doi.org/10.1016/j.molmet.2017.08.010.Baggio L.L., Ussher J.R., McLean B.A., Cao X., Kabir M.G., Mulvihill E.E. et al. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice. Mol Metab. 2017;6(11):1339–1349. https://doi.org/10.1016/j.molmet.2017.08.010.Szablowski J.O., Lee-Gosselin A., Lue B., Malounda D., Shapiro M.G. Acoustically targeted chemogenetics for the non-invasive control of neural circuits. Nat Biomed Eng. 2018;2(7):475–484. https://doi.org/10.1038/s41551-018-0258-2.Szablowski J.O., Lee-Gosselin A., Lue B., Malounda D., Shapiro M.G. Acoustically targeted chemogenetics for the non-invasive control of neural circuits. Nat Biomed Eng. 2018;2(7):475–484. https://doi.org/10.1038/s41551-018-0258-2.Ерофеев А.И., Матвеев М.В., Терехин С.Г., Захарова О.А., Плотникова П.В., Власова О.Л. Оптогенетика – новый метод исследования нейрональной активности. Научно-технические ведомости Санкт-Петербургского государственного политехнического университета. Физико-математические науки. 2015;(3):61–74. Режим доступа: https://physmath.spbstu.ru/article/2015.29.7.Erofeev A.I., Matveev M.V., Terekhin S.G., Zakharova O.A., Plotnikova P.V., Vlasova O.L. The new method for studying neuronal activity: optogenetics. St Petersburg Polytechnical University Journal: Physics and Mathematics. 2015;(3):61–74. (In Russ.) Available at: https://physmath.spbstu.ru/article/2015.29.7.Gaykema R.P., Newmyer B.A., Ottolini M., Raje V., Warthen D.M., Lambeth P.S. et al. Activation of murine pre-proglucagon – producing neurons reduces food intake and body weight. J Сlin Invest. 2017;127(3):1031–1045. https://doi.org/10.1172/JCI81335.Gaykema R.P., Newmyer B.A., Ottolini M., Raje V., Warthen D.M., Lambeth P.S. et al. Activation of murine pre-proglucagon – producing neurons reduces food intake and body weight. J Сlin Invest. 2017;127(3):1031–1045. https://doi.org/10.1172/JCI81335.Burmeister M.A., Ayala J.E., Smouse H., Landivar-Rocha A., Brown J.D., Drucker D.J. et al. The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. Diabetes. 2017;66(2):372–384. https://doi.org/10.2337/db16-1102.Burmeister M.A., Ayala J.E., Smouse H., Landivar-Rocha A., Brown J.D., Drucker D.J. et al. The hypothalamic glucagon-like peptide 1 receptor is sufficient but not necessary for the regulation of energy balance and glucose homeostasis in mice. Diabetes. 2017;66(2):372–384. https://doi.org/10.2337/db16-1102.Kooijman S., Wang Y., Parlevliet E.T., Boon M.R., Edelschaap D., Snaterse G. et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia. 2015;58(11):2637–2646. https://doi.org/10.1007/s00125-015-3727-0.Kooijman S., Wang Y., Parlevliet E.T., Boon M.R., Edelschaap D., Snaterse G. et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia. 2015;58(11):2637–2646. https://doi.org/10.1007/s00125-015-3727-0.Lockie S.H., Heppner K.M., Chaudhary N., Chabenne J.R., Morgan D.A., Veyrat-Durebex C. et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61(11):2753–2762. https://doi.org/10.2337/db11-1556.Lockie S.H., Heppner K.M., Chaudhary N., Chabenne J.R., Morgan D.A., Veyrat-Durebex C. et al. Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling. Diabetes. 2012;61(11):2753–2762. https://doi.org/10.2337/db11-1556.Beiroa D., Imbernon M., Gallego R., Senra A., Herranz D., Villarroya F. et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63(10):3346–3358. https://doi.org/10.2337/db14-0302.Beiroa D., Imbernon M., Gallego R., Senra A., Herranz D., Villarroya F. et al. GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes. 2014;63(10):3346–3358. https://doi.org/10.2337/db14-0302.Brierley D.I., de Lartigue G. Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating. Br J Pharmacol. 2022;179(4):584–599. https://doi.org/10.1111/bph.15603.Brierley D.I., de Lartigue G. Reappraising the role of the vagus nerve in GLP‐1‐mediated regulation of eating. Br J Pharmacol. 2022;179(4):584–599. https://doi.org/10.1111/bph.15603.Frias J.P., Bonora E., Ruiz L.N., Li Y.G., Yu Z., Milicevic Z. et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765–773. https://doi.org/10.2337/dc20-1473.Frias J.P., Bonora E., Ruiz L.N., Li Y.G., Yu Z., Milicevic Z. et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765–773. https://doi.org/10.2337/dc20-1473.Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. https://doi.org/10.1056/NEJMoa2028395.Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V. et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–1124. https://doi.org/10.1056/NEJMoa2028395.O’Neil P.M., Birkenfeld A.L., McGowan B., Mosenzon O., Pedersen S.D., Wharton S. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649. https://doi.org/10.1016/S0140-6736(18)31773-2.O’Neil P.M., Birkenfeld A.L., McGowan B., Mosenzon O., Pedersen S.D., Wharton S. et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649. https://doi.org/10.1016/S0140-6736(18)31773-2.Lomonaco R., Leiva E.G., Bril F., Shrestha S., Mansour L., Budd J. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44(2):399–406. https://doi.org/10.2337/dc20-1997.Lomonaco R., Leiva E.G., Bril F., Shrestha S., Mansour L., Budd J. et al. Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44(2):399–406. https://doi.org/10.2337/dc20-1997.Seko Y., Sumida Y., Tanaka S., Mori K., Taketani H., Ishiba H. et al. Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47(11):1206–1211. https://doi.org/10.1111/hepr.12837.Seko Y., Sumida Y., Tanaka S., Mori K., Taketani H., Ishiba H. et al. Effect of 12‐week dulaglutide therapy in Japanese patients with biopsy‐proven non‐alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47(11):1206–1211. https://doi.org/10.1111/hepr.12837.Mantovani A., Petracca G., Beatrice G., Csermely A., Lonardo A., Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73. https://doi.org/10.3390/metabo11020073.Mantovani A., Petracca G., Beatrice G., Csermely A., Lonardo A., Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites. 2021;11(2):73. https://doi.org/10.3390/metabo11020073.Patel Chavez C., Cusi K., Kadiyala S. The emerging role of glucagon-like Peptide-1 receptor agonists for the management of NAFLD. J Clin Endocrinol Metab. 2022;107(1):29–38. https://doi.org/10.1210/clinem/dgab578.Patel Chavez C., Cusi K., Kadiyala S. The emerging role of glucagon-like Peptide-1 receptor agonists for the management of NAFLD. J Clin Endocrinol Metab. 2022;107(1):29–38. https://doi.org/10.1210/clinem/dgab578.Ghosal S., Datta D., Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11(1):1–8. https://doi.org/10.1038/s41598-021-01663-y.Ghosal S., Datta D., Sinha B. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D). Sci Rep. 2021;11(1):1–8. https://doi.org/10.1038/s41598-021-01663-y.

The authors declare that there are no conflicts of interest present.